Phase 3, Randomized, Double Blind, Placebo Controlled Study Of The Safety And Efficacy Of 2 Doses Of CP 690,550 In Patients With Active Rheumatoid Arthritis On Background DMARDS.

Trial Profile

Phase 3, Randomized, Double Blind, Placebo Controlled Study Of The Safety And Efficacy Of 2 Doses Of CP 690,550 In Patients With Active Rheumatoid Arthritis On Background DMARDS.

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Jun 2017

At a glance

  • Drugs Tofacitinib (Primary)
  • Indications Rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms ORAL-Sync
  • Sponsors Pfizer
  • Most Recent Events

    • 17 Jun 2017 Results of a post hoc analysis assessing magnitude and durability of early onset of effect of tofacitinib in ORAL Solo and ORAL Sync trials presented at the 18th Annual Congress of the European League Against Rheumatism
    • 17 Jun 2017 Result of pooled post-hoc analysis from six phase III studies including this study presented at the 18th Annual Congress of the European League Against Rheumatism
    • 17 Jun 2017 Results of post hoc analysis, presented at the 18th Annual Congress of the European League Against Rheumatism
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top